Soligenix's HyBryte Therapy Shows Positive Safety Profile in Phase 3 CTCL Trial
Soligenix's HyBryte therapy demonstrated a positive safety profile in its ongoing Phase 3 FLASH2 study for cutaneous T-cell lymphoma, maintaining progress toward potential regulatory approval and commercialization as a first-line treatment option.
The Data Monitoring Committee for Soligenix Inc. has completed its initial safety review of the confirmatory Phase 3 FLASH2 study evaluating HyBryte for cutaneous T-cell lymphoma, reporting no safety concerns and confirming the therapy maintains an acceptable safety profile consistent with prior clinical trials. This positive safety assessment represents a critical milestone for the late-stage biopharmaceutical company as it advances toward potential regulatory approval and commercialization of what could become a first-line treatment option for patients suffering from this rare form of cancer.
Enrollment in the FLASH2 trial continues to progress according to schedule, with the company expecting to provide an update in the fourth quarter of 2025. A blinded interim efficacy analysis is planned for the first half of 2026, which will provide additional insights into the therapy's effectiveness without compromising the study's integrity. The current trial builds upon the company's earlier statistically significant Phase 3 results and additional supportive studies that have demonstrated HyBryte's efficacy and tolerability profile.
The FLASH2 study represents a confirmatory trial designed to validate previous positive results, a necessary step in the regulatory pathway toward potential commercialization worldwide. HyBryte utilizes synthetic hypericin as a novel photodynamic therapy that employs safe visible light for treating cutaneous T-cell lymphoma, offering a potentially significant advancement for patients with limited treatment options. The therapy's development aligns with Soligenix's focus on addressing unmet medical needs in rare diseases, particularly in the specialized biotherapeutics segment where HyBryte represents a cornerstone program.
Additional information about the company's developments can be found in their newsroom at https://ibn.fm/SNGX. The successful progression of the FLASH2 trial without safety concerns reinforces the potential of HyBryte to address significant treatment gaps in cutaneous T-cell lymphoma management, particularly as the therapy moves closer to potential regulatory submissions and commercialization decisions that could impact patient care globally.